Elevance Health financials
$392.73−0.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $199.13B | $177.01B | $171.34B | $156.59B |
| Gross profit | $50.90B | $49.44B | $47.01B | $39.95B |
| Gross margin | 25.6% | 27.9% | 27.4% | 25.5% |
| Operating income | $8.11B | $9.09B | $8.74B | $8.45B |
| Net income | $5.66B | $5.98B | $5.99B | $5.89B |
| Net margin | 2.8% | 3.4% | 3.5% | 3.8% |
| Diluted EPS | $25.21 | $25.68 | $25.22 | $24.28 |
| EBITDA | $9.66B | $10.48B | $10.49B | $10.13B |
| Operating cash flow | $4.29B | $5.81B | $8.06B | $8.40B |
| Free cash flow | $3.17B | $4.55B | $6.76B | $7.25B |
| Diluted shares | 224.6M | 232.9M | 237.4M | 242.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $9.49B | $8.29B | $6.53B | $7.39B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $32.05B | $31.23B | $25.12B | $24.11B |
| Total assets | $121.49B | $116.89B | $108.93B | $102.75B |
| Total liabilities | $77.47B | $75.46B | $69.52B | $66.42B |
| Shareholders' equity | $44.03B | $41.43B | $39.41B | $36.33B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology